Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Yuji Yamada, MD, Hiroyuki Ohbe, MD MPH, Hideo Yasunaga, MD PhD, Yoshitaka Miyakawa, MD PhD

Blood (2019) 134 (Supplement_1): 2374.

https://doi.org/10.1182/blood-2019-125170

Published: 2019

Journal Articles

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Yoshitaka Miyakawa, MD, PhD, Shinya Katsutani, MD, PhD, Takahiro Yano, MD, PhD, Shosaku Nomura, MD, PhD, Kaichi Nishiwaki, MD, Yoshiaki Tomiyama, MD, PhD, Masaaki Higashihara, MD, PhD, Yukari Shirasugi, MD, PhD, Masakatsu Nishikawa, MD, PhD, Katsutoshi Ozaki, MD, PhD, Kayoko Kikuchi, Takayuki Abe, PhD, Yuji Sato, MD, PhD, Yuzuru Kanakura, Kingo Fujimura, MD, PhD, Yasuo Ikeda, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 3554.

https://doi.org/10.1182/blood.V122.21.3554.3554

Published: 2013

Journal Articles

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

Eri Matsuki, MD, Yoshitaka Miyakawa, MD, PhD, Shuichi Asakawa, Yuiko Tsukada, MD, Kenji Yokoyama, MD, PhD, Jun Kudoh, Shinichiro Okamoto, MD, PhD

Blood (2010) 116 (21): 4451.

https://doi.org/10.1182/blood.V116.21.4451.4451

Published: 2010

Journal Articles

A Novel Factor XII Mutation, FXII Tokyo (R84P), Causing Factor XII Deficiency In a Patient with Hereditary Spastic Paraplegia

Eri Matsuki, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2010) 116 (21): 1404.

https://doi.org/10.1182/blood.V116.21.1404.1404

Published: 2010

Journal Articles

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Yoshiaki Tomiyama, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD, Shinya Katsutani, MD, Akiro Kimura, MD, Yasushi Okoshi, MD, PhD, Haruhiko Ninomiya, MD, PhD, Hiroshi Kosugi, MD, PhD, Shosaku Nomura, MD, Katsutoshi Ozaki, MD, Yasuo Ikeda, MD, Nobuyuki Koh, Koichi Katsura, MD, PhD, Yuzuru Kanakura, MD, PhD

Blood (2009) 114 (22): 1324.

https://doi.org/10.1182/blood.V114.22.1324.1324

Published: 2009

Journal Articles

Effectiveness of a Novel Humanized VB22B Minibody against Human TPO Receptor Compared with Recombinant TPO and Eltrombopag Using Primary Human CD34+ Cells and Platelets.

Eri Matsuki, MD, Akiko Yamane, MD, PhD, Shinichiro Okamoto, MD, PhD, Yoshitaka Miyakawa, MD, PhD

Blood (2009) 114 (22): 4559.

https://doi.org/10.1182/blood.V114.22.4559.4559

Published: 2009

Journal Articles

Interferon-α2b-Induced Thrombocytopenia Is Caused by Inhibition of Cytoplasmic Maturation and Platelet Production, but Not Proliferation and Endomitosis in Human Megakaryocytes.

Akiko Yamane, MD, Takanori Nakamura, Mamoru Ito, Yasuyuki Ohnishi, Yasuo Ikeda, MD, PhD, Yoshitaka Miyakawa, MD, PhD

Blood (2007) 110 (11): 2195.

https://doi.org/10.1182/blood.V110.11.2195.2195

Published: 2007

NARROW

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

A Novel Factor XII Mutation, FXII Tokyo (R84P), Causing Factor XII Deficiency In a Patient with Hereditary Spastic Paraplegia

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Effectiveness of a Novel Humanized VB22B Minibody against Human TPO Receptor Compared with Recombinant TPO and Eltrombopag Using Primary Human CD34+ Cells and Platelets.

Interferon-α2b-Induced Thrombocytopenia Is Caused by Inhibition of Cytoplasmic Maturation and Platelet Production, but Not Proliferation and Endomitosis in Human Megakaryocytes.

Email alerts

ASH Publications

American Society of Hematology

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR

A Novel Factor XII Mutation, FXII Tokyo (R84P), Causing Factor XII Deficiency In a Patient with Hereditary Spastic Paraplegia

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Effectiveness of a Novel Humanized VB22B Minibody against Human TPO Receptor Compared with Recombinant TPO and Eltrombopag Using Primary Human CD34+ Cells and Platelets.

Interferon-α2b-Induced Thrombocytopenia Is Caused by Inhibition of Cytoplasmic Maturation and Platelet Production, but Not Proliferation and Endomitosis in Human Megakaryocytes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only